ANDA 76675, held by Ph Health. Desogestrel; Ethinyl Estradiol.
As of Nov 16, 2026, ANDA 76675 (Emoquette), held by Ph Health, was first approved by FDA on Feb 25, 2011, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 25, 2011 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Emoquette0.15MG;0.03MG · tablet;oral-28 | Desogestrel; Ethinyl Estradiol | Discontinued |
| Apr 29, 2022 | Supplement 13Labeling · Standard review | Approved | None posted |
| Mar 17, 2022 | Supplement 12Labeling · Standard review | Approved | None posted |
| Aug 9, 2017 | Supplement 11Labeling · Standard review | Approved | None posted |
| May 26, 2016 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 13, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 27, 2013 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 25, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters